These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11596833)

  • 1. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.
    Lubeck DP
    Pharmacoeconomics; 2001; 19(8):811-8. PubMed ID: 11596833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Peterson AN; Doyle J; Huse DM
    Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of managed care on the use of biologic agents for rheumatoid arthritis.
    Yelin EH; Trupin LS; Katz PP
    Arthritis Rheum; 2005 Jun; 53(3):423-30. PubMed ID: 15934109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings.
    Ward MM; Lubeck D; Leigh JP
    J Rheumatol; 1998 Apr; 25(4):641-9. PubMed ID: 9558163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.
    Lanes SF; Lanza LL; Radensky PW; Yood RA; Meenan RF; Walker AM; Dreyer NA
    Arthritis Rheum; 1997 Aug; 40(8):1475-81. PubMed ID: 9259428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managed care implications in managing rheumatoid arthritis.
    Owens GM
    Am J Manag Care; 2014 May; 20(7 Suppl):S145-52. PubMed ID: 25180623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
    Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
    Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and impact of managed care for persons with rheumatoid arthritis in 1994 and 1999.
    Yelin E; Trupin L; Katz P
    Arthritis Rheum; 2002 Apr; 47(2):172-80. PubMed ID: 11954011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission.
    Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
    Ann Rheum Dis; 2013 Oct; 72(10):1664-8. PubMed ID: 23117244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings.
    Yelin EH; Criswell LA; Feigenbaum PG
    JAMA; 1996 Oct; 276(13):1048-53. PubMed ID: 8847766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting.
    Gallup E
    Manag Care Interface; 2001 Jul; 14(7):52-4, 57-8, 69. PubMed ID: 11481817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
    Fleming E; Lien H; Ma CT; McGuire TG
    J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health service utilization among Alzheimer's disease patients: evidence from managed care.
    Frytak JR; Henk HJ; Zhao Y; Bowman L; Flynn JA; Nelson M
    Alzheimers Dement; 2008 Sep; 4(5):361-7. PubMed ID: 18790463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
    Michaud K; Messer J; Choi HK; Wolfe F
    Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example.
    Schwenkglenks M; Preiswerk G; Lehner R; Weber F; Szucs TD
    J Epidemiol Community Health; 2006 Jan; 60(1):24-30. PubMed ID: 16361451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of managed fee-for-service and direct reimbursement.
    van der Wal CJ; Smithwick CL
    J Am Coll Dent; 1997; 64(3):28-36. PubMed ID: 9420385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing cost and quality in fee-for-service versus managed care.
    Eddy DM
    Health Aff (Millwood); 1997; 16(3):162-73. PubMed ID: 9141333
    [No Abstract]   [Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.
    Verstappen SM; Jacobs JW; van der Heijde DM; van der Linden S; Verhoef CM; Bijlsma JW; Boonen A
    Ann Rheum Dis; 2007 Jun; 66(6):727-31. PubMed ID: 17172249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.